Status:
RECRUITING
The Effect of Perception of Improvement in Patients With Fibromyalgia
Lead Sponsor:
Istanbul Medeniyet University
Conditions:
Fibromyalgia
Eligibility:
FEMALE
25-55 years
Phase:
NA
Brief Summary
Fibromyalgia (FM) is a chronic pain syndrome characterized by impaired perception, transmission, and processing of nociceptive stimuli and causing widespread pain. Pain in FM is the disease itself and...
Eligibility Criteria
Inclusion
- Diagnosed with Fibromyalgia at least 1 year ago according to ACR criteria
- Age range 25-55
- Female
- Scored at least 24 on the Mini-Mental State Assessment Test
- Reported weekly pain intensity of at least 40 mm on the Visual Analog Scale
- Be on a stable dose of medication for at least 6 months (serotonin norepinephrine reuptake inhibitors \[e.g., duloxetine, milnacipran\]; alpha 2-delta receptor ligand \[e.g., pregabalin\]; gabapentinoids)
Exclusion
- Having inflammatory rheumatic disease, malignancy, neurological disease, connective tissue disease, severe anemia, uncontrolled endocrine diseases
- Body Mass Index (BMI) ≥ 30 Kg/m2
- Being pregnant
- Having inability to understand, read and speak Turkish
- Having difficulty in hearing and seeing
- Having any metallic or electronic device in the body that will create incompatibility with the magnetic field in the fMRI scan Having any disease diagnosis (serious psychotic disorder, delirium, mental retardation, epilepsy, heart disease, lung diseases, etc.) that may prevent participation in the evaluation and training to be conducted within the scope of the research
Key Trial Info
Start Date :
August 13 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 15 2026
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT06508385
Start Date
August 13 2024
End Date
August 15 2026
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nilüfer kablan
Istanbul, Kartal, Turkey (Türkiye)